$ENTO News
Last published 11mo ago
- 11mo agoENTOEntero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"ACCESS NewswireBOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. today announced that it will change its name to GridAI Technologies Corp., effective at 12:01
- 11mo agoENTOENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center CustomerACCESS NewswireBOCA RATON, FLORIDA / ACCESS Newswire / November 19, 2025 / Entero Therapeutics, Inc. today announced that its subsidiary Grid AI has executed a Letter of
- 12mo agoENTOEntero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure StrategyACCESS NewswireTimed with a sharp acceleration in AI-data-center expansion, with more than $60B in new projects announced in the last 90 days. BOCA RATON, FL / ACCESS Newswire / November 13, 2025 / Entero Therapeutics, Inc.
- 1y agoENTOEntero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV GridACCESS NewswireIntegration boosts Grid AI's deployment capacity as AI data-center power demand approaches 50 GW, growing by over 165% through 2030i BOCA RATON, FL / ACCESS Newswire / November 6, 2025 / Entero Therapeutics, Inc.
- 1y agoENTOEntero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)ACCESS NewswireBOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics has just made one of the boldest moves in its history, a reinvention that trades long biotech timelines for immediate impact. By
- 1y agoENTOEntero Regains Nasdaq Compliance With Grid AI AcquisitionACCESS NewswireBOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics, Inc. is pleased to announce that, as a result of the acquisition of 100% of Grid AI
- 1y agoENTOEntero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power GridACCESS NewswireBOCA RATON, FL / ACCESS Newswire / October 16, 2025 / Entero Therapeutics, Inc. a company pioneering innovation at the intersection of biotechnology and
- 1y agoENTOFrom Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO)ACCESS NewswireBOCA RATON, FL, NY / ACCESS Newswire / October 14, 2025 / Entero Therapeutics has reinvented itself in a way few public companies dare. By acquiring GRID AI, it has stepped directly into one of the most
- 1y agoENTOEntero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind ItACCESS NewswireBOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics didn't tiptoe into reinvention. It jumped. The company, once known for enzymes and patient trials, is now in the grid game,
- 1y agoENTOENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AIACCESS NewswireTransaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions BOCA
- 1y agoENTOEntero Therapeutics Appoints Richard Paolone as CEOGlobeNewswireBOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted,
- 1y agoENTOEntero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board MembersGlobeNewswireBOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted,
- 1y agoENTOPFCPIKPULMKuehn Law Encourages ENTO, PULM, PIK, and PFC Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoENTOEntero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO ForumGlobeNewswireBOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
- 1y agoENTOEntero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical CompanyGlobeNewswireProposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey's next-gen, first-in-class ADC-rivalling, nano-immunoconjugates ("NIC") platform and therapeutic products
- 2y agoENTOOCSONCOVRNAVirometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the BoardBusiness WireVirometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today
- 2y agoENTOEntero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault HoldingsGlobeNewswireBOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
- 2y agoENTOEntero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-QGlobeNewswireBOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
- 2y agoENTOEntero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development ProgramGlobeNewswireBOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
- 2y agoENTOEntero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross ProceedsGlobeNewswireBOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. ("Entero" or the "Company") (NASDAQ:ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted,
- 2y agoENTOEntero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease SymposiumGlobeNewswireBOCA RATON, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
- 2y agoENTOEntero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac DiseaseGlobeNewswireNew VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the potential importance of VCIEL
- 2y agoENTOEntero Therapeutics to Present Corporate Update at 2024 BIO International ConventionGlobeNewswireBOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on
- 2y agoENTOEntero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) ConferenceGlobeNewswireBOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
- 2y agoFWBIENTOFirst Wave BioPharma Changes Name to Entero TherapeuticsGlobeNewswireRebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is "ENTO" effective May 17, 2024 BOCA RATON, Fla.,